Navigation Links
Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Date:12/8/2008

SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of BYETTA(R) (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control. It is likely that this review will not be complete by the end of 2008, and may extend into 2009.

"Our discussions with the FDA continue to progress and we remain confident in the strength of our regulatory submission," said Orville G. Kolterman, senior vice president of research and development at Amylin Pharmaceuticals. "Importantly, we have not received any request for additional studies. We look forward to working closely with the agency as needed throughout the review process."

The regulatory application for use of BYETTA as monotherapy was submitted in the first quarter of 2008. The FDA is also reviewing several other BYETTA prescribing information updates submitted by the companies, including revision of safety language and conversion of physician labeling to the new standard format.

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

About Diabetes

Diabetes affects more than 23 million in the United States and an estimated 246 million adults worldwide.(i,ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses. (iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is the most common side effect when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For full prescribing information, visit www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit, www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition; unexpected new data; safety and technical issues; clinical trials not confirming previous results; pre-clinical trials not predicting future results; or regulatory applications, including the regulatory application mentioned in this press release, not being submitted in a timely manner or receiving regulatory approval. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no duty to update these forward-looking statements.

i The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A. Accessed June 2, 2008.

ii "All About Diabetes." American Diabetes Association. Available at: http://www.diabetes.org/about-diabetes.jsp. Accessed June 8, 2008.

iii "Direct and Indirect Costs of Diabetes in the United States." American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed June 8, 2008.

iv Saydah SH, Fradkin J and Cowie CC. "Poor Control of Risk Factors for Vascular Disease Among Adults with Previously Diagnosed Diabetes." JAMA: 291(3), January 21, 2004.

v Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-47.

vi Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2007;30 Suppl 1:S48-65.

vii Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )

    P-LLY


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. ... provides instant absorption from the mouth into the bloodstream. Far outpacing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new ... now available on the App Store and Google Play . Florida-based ... the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
(Date:2/22/2017)... North Carolina (PRWEB) , ... February 22, 2017 , ... ... of cats and 54% of dogs, according to the Association for Pet Obesity Prevention ... disagreed on key pet food issues such as the benefits of corn and grains, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- Corin Group announced today the launch of the Humelock ... with both a massive rotator cuff tear and a ... cuff tear arthropathy, causes pain and reduced mobility in ... Reversed Shoulder System, which was developed by FX Solutions, ... Lyon, France , received FDA clearance for ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drug Development Pipeline Review, 2016" report to their offering. ... ... disorders worldwide, and approximately one-third of the US population suffers ... decades, the majority of the dermatology market has remained saturated ...
(Date:2/22/2017)... Research and Markets has announced the addition of ... Small Molecule Drugs), By Route of Administration (Systemic, Topical), By ... report to their offering. ... The global psoriasis drugs market is anticipated ... report provides a detailed analysis of the current and future ...
Breaking Medicine Technology: